nodes	percent_of_prediction	percent_of_DWPC	metapath
Prasugrel—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.166	0.244	CbGbCtD
Prasugrel—CYP2C19—Progesterone—uterine cancer	0.132	0.194	CbGbCtD
Prasugrel—CYP2C9—Progesterone—uterine cancer	0.11	0.162	CbGbCtD
Prasugrel—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0963	0.142	CbGbCtD
Prasugrel—CYP3A4—Progesterone—uterine cancer	0.0638	0.094	CbGbCtD
Prasugrel—CYP2B6—Doxorubicin—uterine cancer	0.0634	0.0934	CbGbCtD
Prasugrel—CYP3A4—Etoposide—uterine cancer	0.0285	0.0421	CbGbCtD
Prasugrel—P2RY12—artery—uterine cancer	0.0214	0.229	CbGeAlD
Prasugrel—CYP3A4—Doxorubicin—uterine cancer	0.0195	0.0287	CbGbCtD
Prasugrel—Thrombotic thrombocytopenic purpura—Medroxyprogesterone Acetate—uterine cancer	0.0122	0.0581	CcSEcCtD
Prasugrel—P2RY12—epithelium—uterine cancer	0.00811	0.0869	CbGeAlD
Prasugrel—CES2—myometrium—uterine cancer	0.00659	0.0706	CbGeAlD
Prasugrel—CES2—uterine cervix—uterine cancer	0.00513	0.055	CbGeAlD
Prasugrel—CES2—smooth muscle tissue—uterine cancer	0.00498	0.0534	CbGeAlD
Prasugrel—CES2—decidua—uterine cancer	0.00489	0.0524	CbGeAlD
Prasugrel—CES2—renal system—uterine cancer	0.0048	0.0514	CbGeAlD
Prasugrel—CES2—endometrium—uterine cancer	0.00464	0.0497	CbGeAlD
Prasugrel—Neoplasm malignant—Progesterone—uterine cancer	0.0045	0.0214	CcSEcCtD
Prasugrel—CES2—mammalian vulva—uterine cancer	0.00449	0.0481	CbGeAlD
Prasugrel—CES2—uterus—uterine cancer	0.00427	0.0458	CbGeAlD
Prasugrel—Neoplasm malignant—Medroxyprogesterone Acetate—uterine cancer	0.00408	0.0194	CcSEcCtD
Prasugrel—Rectal haemorrhage—Medroxyprogesterone Acetate—uterine cancer	0.00385	0.0184	CcSEcCtD
Prasugrel—CES2—female reproductive system—uterine cancer	0.00384	0.0412	CbGeAlD
Prasugrel—CES2—female gonad—uterine cancer	0.0035	0.0375	CbGeAlD
Prasugrel—CES2—vagina—uterine cancer	0.00348	0.0372	CbGeAlD
Prasugrel—Neoplasm—Progesterone—uterine cancer	0.00347	0.0166	CcSEcCtD
Prasugrel—Neoplasm—Medroxyprogesterone Acetate—uterine cancer	0.00315	0.015	CcSEcCtD
Prasugrel—Pain in extremity—Progesterone—uterine cancer	0.00279	0.0133	CcSEcCtD
Prasugrel—Haematochezia—Epirubicin—uterine cancer	0.00274	0.013	CcSEcCtD
Prasugrel—Pericardial effusion—Epirubicin—uterine cancer	0.00269	0.0128	CcSEcCtD
Prasugrel—Cerebrovascular accident—Medroxyprogesterone Acetate—uterine cancer	0.00258	0.0123	CcSEcCtD
Prasugrel—Haematochezia—Doxorubicin—uterine cancer	0.00253	0.0121	CcSEcCtD
Prasugrel—Pain in extremity—Medroxyprogesterone Acetate—uterine cancer	0.00253	0.012	CcSEcCtD
Prasugrel—Pericardial effusion—Doxorubicin—uterine cancer	0.00248	0.0118	CcSEcCtD
Prasugrel—CES2—lymph node—uterine cancer	0.00225	0.0241	CbGeAlD
Prasugrel—Body temperature increased—Carboplatin—uterine cancer	0.00206	0.00983	CcSEcCtD
Prasugrel—Gingival bleeding—Epirubicin—uterine cancer	0.00194	0.00925	CcSEcCtD
Prasugrel—Haemoglobin—Progesterone—uterine cancer	0.00194	0.00924	CcSEcCtD
Prasugrel—Haemorrhage—Progesterone—uterine cancer	0.00193	0.0092	CcSEcCtD
Prasugrel—Urinary tract disorder—Progesterone—uterine cancer	0.00191	0.00908	CcSEcCtD
Prasugrel—Oedema peripheral—Progesterone—uterine cancer	0.0019	0.00906	CcSEcCtD
Prasugrel—Urethral disorder—Progesterone—uterine cancer	0.00189	0.00902	CcSEcCtD
Prasugrel—Epistaxis—Medroxyprogesterone Acetate—uterine cancer	0.00184	0.00876	CcSEcCtD
Prasugrel—Eye disorder—Progesterone—uterine cancer	0.0018	0.00859	CcSEcCtD
Prasugrel—Gingival bleeding—Doxorubicin—uterine cancer	0.0018	0.00856	CcSEcCtD
Prasugrel—Bradycardia—Medroxyprogesterone Acetate—uterine cancer	0.00178	0.00848	CcSEcCtD
Prasugrel—Haemoglobin—Medroxyprogesterone Acetate—uterine cancer	0.00176	0.00838	CcSEcCtD
Prasugrel—Angiopathy—Progesterone—uterine cancer	0.00175	0.00834	CcSEcCtD
Prasugrel—Haemorrhage—Medroxyprogesterone Acetate—uterine cancer	0.00175	0.00833	CcSEcCtD
Prasugrel—Immune system disorder—Progesterone—uterine cancer	0.00174	0.00831	CcSEcCtD
Prasugrel—Mediastinal disorder—Progesterone—uterine cancer	0.00174	0.00829	CcSEcCtD
Prasugrel—CYP2B6—renal system—uterine cancer	0.00173	0.0186	CbGeAlD
Prasugrel—Urinary tract disorder—Medroxyprogesterone Acetate—uterine cancer	0.00173	0.00823	CcSEcCtD
Prasugrel—Oedema peripheral—Medroxyprogesterone Acetate—uterine cancer	0.00172	0.00821	CcSEcCtD
Prasugrel—Urethral disorder—Medroxyprogesterone Acetate—uterine cancer	0.00171	0.00817	CcSEcCtD
Prasugrel—Eye disorder—Medroxyprogesterone Acetate—uterine cancer	0.00163	0.00779	CcSEcCtD
Prasugrel—Back pain—Progesterone—uterine cancer	0.00162	0.00774	CcSEcCtD
Prasugrel—CYP2C19—vagina—uterine cancer	0.0016	0.0172	CbGeAlD
Prasugrel—Angiopathy—Medroxyprogesterone Acetate—uterine cancer	0.00159	0.00756	CcSEcCtD
Prasugrel—Immune system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00158	0.00753	CcSEcCtD
Prasugrel—Mediastinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00158	0.00751	CcSEcCtD
Prasugrel—Anaemia—Progesterone—uterine cancer	0.00155	0.0074	CcSEcCtD
Prasugrel—Angioedema—Progesterone—uterine cancer	0.00153	0.00732	CcSEcCtD
Prasugrel—Hyperlipidaemia—Epirubicin—uterine cancer	0.00153	0.00729	CcSEcCtD
Prasugrel—Haemoptysis—Epirubicin—uterine cancer	0.00149	0.0071	CcSEcCtD
Prasugrel—Back pain—Medroxyprogesterone Acetate—uterine cancer	0.00147	0.00702	CcSEcCtD
Prasugrel—Cough—Progesterone—uterine cancer	0.00147	0.00699	CcSEcCtD
Prasugrel—Hypertension—Progesterone—uterine cancer	0.00145	0.00691	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.00142	0.00677	CcSEcCtD
Prasugrel—Hyperlipidaemia—Doxorubicin—uterine cancer	0.00141	0.00674	CcSEcCtD
Prasugrel—Anaemia—Medroxyprogesterone Acetate—uterine cancer	0.00141	0.00671	CcSEcCtD
Prasugrel—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.00139	0.00663	CcSEcCtD
Prasugrel—CYP2B6—female reproductive system—uterine cancer	0.00139	0.0149	CbGeAlD
Prasugrel—Haemoptysis—Doxorubicin—uterine cancer	0.00138	0.00656	CcSEcCtD
Prasugrel—CYP2C9—female reproductive system—uterine cancer	0.00137	0.0147	CbGeAlD
Prasugrel—Anaphylactic shock—Progesterone—uterine cancer	0.00137	0.00653	CcSEcCtD
Prasugrel—Skin disorder—Progesterone—uterine cancer	0.00133	0.00635	CcSEcCtD
Prasugrel—CYP3A4—renal system—uterine cancer	0.00131	0.014	CbGeAlD
Prasugrel—Neoplasm malignant—Epirubicin—uterine cancer	0.00129	0.00615	CcSEcCtD
Prasugrel—ALB—lymph node—uterine cancer	0.00129	0.0138	CbGeAlD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.00129	0.00613	CcSEcCtD
Prasugrel—Hypotension—Progesterone—uterine cancer	0.00128	0.00611	CcSEcCtD
Prasugrel—CYP2B6—vagina—uterine cancer	0.00125	0.0134	CbGeAlD
Prasugrel—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.00124	0.00592	CcSEcCtD
Prasugrel—Dyspnoea—Progesterone—uterine cancer	0.00122	0.00583	CcSEcCtD
Prasugrel—Rectal haemorrhage—Epirubicin—uterine cancer	0.00122	0.00581	CcSEcCtD
Prasugrel—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.00122	0.0058	CcSEcCtD
Prasugrel—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00121	0.00575	CcSEcCtD
Prasugrel—Neoplasm malignant—Doxorubicin—uterine cancer	0.00119	0.00569	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Progesterone—uterine cancer	0.00118	0.00564	CcSEcCtD
Prasugrel—Fatigue—Progesterone—uterine cancer	0.00118	0.00563	CcSEcCtD
Prasugrel—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.00116	0.00553	CcSEcCtD
Prasugrel—Rectal haemorrhage—Doxorubicin—uterine cancer	0.00113	0.00538	CcSEcCtD
Prasugrel—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.00111	0.00528	CcSEcCtD
Prasugrel—Anaemia—Dactinomycin—uterine cancer	0.0011	0.00523	CcSEcCtD
Prasugrel—Body temperature increased—Progesterone—uterine cancer	0.00108	0.00517	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00107	0.00511	CcSEcCtD
Prasugrel—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00107	0.0051	CcSEcCtD
Prasugrel—Leukopenia—Dactinomycin—uterine cancer	0.00106	0.00507	CcSEcCtD
Prasugrel—CYP3A4—female reproductive system—uterine cancer	0.00105	0.0112	CbGeAlD
Prasugrel—Hypersensitivity—Progesterone—uterine cancer	0.00101	0.00481	CcSEcCtD
Prasugrel—Ecchymosis—Epirubicin—uterine cancer	0.000996	0.00475	CcSEcCtD
Prasugrel—Neoplasm—Epirubicin—uterine cancer	0.000996	0.00475	CcSEcCtD
Prasugrel—Asthenia—Progesterone—uterine cancer	0.000984	0.00469	CcSEcCtD
Prasugrel—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000982	0.00468	CcSEcCtD
Prasugrel—Urinary tract disorder—Etoposide—uterine cancer	0.000975	0.00465	CcSEcCtD
Prasugrel—Urethral disorder—Etoposide—uterine cancer	0.000968	0.00461	CcSEcCtD
Prasugrel—Thrombocytopenia—Dactinomycin—uterine cancer	0.000949	0.00452	CcSEcCtD
Prasugrel—Diarrhoea—Progesterone—uterine cancer	0.000938	0.00447	CcSEcCtD
Prasugrel—Eye disorder—Etoposide—uterine cancer	0.000922	0.0044	CcSEcCtD
Prasugrel—Neoplasm—Doxorubicin—uterine cancer	0.000922	0.00439	CcSEcCtD
Prasugrel—Ecchymosis—Doxorubicin—uterine cancer	0.000922	0.00439	CcSEcCtD
Prasugrel—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000915	0.00436	CcSEcCtD
Prasugrel—Dizziness—Progesterone—uterine cancer	0.000907	0.00432	CcSEcCtD
Prasugrel—Angiopathy—Etoposide—uterine cancer	0.000896	0.00427	CcSEcCtD
Prasugrel—Immune system disorder—Etoposide—uterine cancer	0.000892	0.00425	CcSEcCtD
Prasugrel—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000891	0.00425	CcSEcCtD
Prasugrel—Mediastinal disorder—Etoposide—uterine cancer	0.00089	0.00424	CcSEcCtD
Prasugrel—Rash—Progesterone—uterine cancer	0.000864	0.00412	CcSEcCtD
Prasugrel—Dermatitis—Progesterone—uterine cancer	0.000864	0.00412	CcSEcCtD
Prasugrel—Headache—Progesterone—uterine cancer	0.000859	0.00409	CcSEcCtD
Prasugrel—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00085	0.00405	CcSEcCtD
Prasugrel—Fatigue—Dactinomycin—uterine cancer	0.000835	0.00398	CcSEcCtD
Prasugrel—Back pain—Etoposide—uterine cancer	0.000831	0.00396	CcSEcCtD
Prasugrel—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000821	0.00392	CcSEcCtD
Prasugrel—Cerebrovascular accident—Epirubicin—uterine cancer	0.000816	0.00389	CcSEcCtD
Prasugrel—Nausea—Progesterone—uterine cancer	0.000814	0.00388	CcSEcCtD
Prasugrel—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.0008	0.00381	CcSEcCtD
Prasugrel—Pain in extremity—Epirubicin—uterine cancer	0.0008	0.00381	CcSEcCtD
Prasugrel—Anaemia—Etoposide—uterine cancer	0.000794	0.00379	CcSEcCtD
Prasugrel—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000783	0.00373	CcSEcCtD
Prasugrel—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000783	0.00373	CcSEcCtD
Prasugrel—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000778	0.00371	CcSEcCtD
Prasugrel—Leukopenia—Etoposide—uterine cancer	0.000769	0.00367	CcSEcCtD
Prasugrel—Body temperature increased—Dactinomycin—uterine cancer	0.000766	0.00365	CcSEcCtD
Prasugrel—Cerebrovascular accident—Doxorubicin—uterine cancer	0.000755	0.0036	CcSEcCtD
Prasugrel—Cough—Etoposide—uterine cancer	0.00075	0.00357	CcSEcCtD
Prasugrel—Hypertension—Etoposide—uterine cancer	0.000742	0.00354	CcSEcCtD
Prasugrel—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.00074	0.00353	CcSEcCtD
Prasugrel—Pain in extremity—Doxorubicin—uterine cancer	0.00074	0.00353	CcSEcCtD
Prasugrel—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000738	0.00352	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000726	0.00346	CcSEcCtD
Prasugrel—Hypersensitivity—Dactinomycin—uterine cancer	0.000714	0.0034	CcSEcCtD
Prasugrel—Anaphylactic shock—Etoposide—uterine cancer	0.000701	0.00334	CcSEcCtD
Prasugrel—Asthenia—Dactinomycin—uterine cancer	0.000695	0.00331	CcSEcCtD
Prasugrel—Thrombocytopenia—Etoposide—uterine cancer	0.000687	0.00327	CcSEcCtD
Prasugrel—Skin disorder—Etoposide—uterine cancer	0.000681	0.00325	CcSEcCtD
Prasugrel—Diarrhoea—Dactinomycin—uterine cancer	0.000663	0.00316	CcSEcCtD
Prasugrel—Hypotension—Etoposide—uterine cancer	0.000655	0.00312	CcSEcCtD
Prasugrel—Dyspnoea—Etoposide—uterine cancer	0.000625	0.00298	CcSEcCtD
Prasugrel—Rash—Dactinomycin—uterine cancer	0.000611	0.00291	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Etoposide—uterine cancer	0.000605	0.00289	CcSEcCtD
Prasugrel—Fatigue—Etoposide—uterine cancer	0.000605	0.00288	CcSEcCtD
Prasugrel—Haematuria—Epirubicin—uterine cancer	0.000588	0.0028	CcSEcCtD
Prasugrel—Epistaxis—Epirubicin—uterine cancer	0.000581	0.00277	CcSEcCtD
Prasugrel—Nausea—Dactinomycin—uterine cancer	0.000576	0.00274	CcSEcCtD
Prasugrel—Bradycardia—Epirubicin—uterine cancer	0.000563	0.00268	CcSEcCtD
Prasugrel—Haemoglobin—Epirubicin—uterine cancer	0.000556	0.00265	CcSEcCtD
Prasugrel—Body temperature increased—Etoposide—uterine cancer	0.000554	0.00264	CcSEcCtD
Prasugrel—Haemorrhage—Epirubicin—uterine cancer	0.000553	0.00264	CcSEcCtD
Prasugrel—Urinary tract disorder—Epirubicin—uterine cancer	0.000546	0.0026	CcSEcCtD
Prasugrel—Oedema peripheral—Epirubicin—uterine cancer	0.000545	0.0026	CcSEcCtD
Prasugrel—Haematuria—Doxorubicin—uterine cancer	0.000544	0.00259	CcSEcCtD
Prasugrel—Urethral disorder—Epirubicin—uterine cancer	0.000542	0.00259	CcSEcCtD
Prasugrel—Epistaxis—Doxorubicin—uterine cancer	0.000538	0.00256	CcSEcCtD
Prasugrel—Bradycardia—Doxorubicin—uterine cancer	0.000521	0.00248	CcSEcCtD
Prasugrel—Eye disorder—Epirubicin—uterine cancer	0.000517	0.00246	CcSEcCtD
Prasugrel—Hypersensitivity—Etoposide—uterine cancer	0.000517	0.00246	CcSEcCtD
Prasugrel—Haemoglobin—Doxorubicin—uterine cancer	0.000515	0.00245	CcSEcCtD
Prasugrel—Haemorrhage—Doxorubicin—uterine cancer	0.000512	0.00244	CcSEcCtD
Prasugrel—Urinary tract disorder—Doxorubicin—uterine cancer	0.000506	0.00241	CcSEcCtD
Prasugrel—Oedema peripheral—Doxorubicin—uterine cancer	0.000504	0.0024	CcSEcCtD
Prasugrel—Asthenia—Etoposide—uterine cancer	0.000503	0.0024	CcSEcCtD
Prasugrel—Angiopathy—Epirubicin—uterine cancer	0.000502	0.00239	CcSEcCtD
Prasugrel—Urethral disorder—Doxorubicin—uterine cancer	0.000502	0.00239	CcSEcCtD
Prasugrel—Immune system disorder—Epirubicin—uterine cancer	0.0005	0.00238	CcSEcCtD
Prasugrel—Mediastinal disorder—Epirubicin—uterine cancer	0.000499	0.00238	CcSEcCtD
Prasugrel—Diarrhoea—Etoposide—uterine cancer	0.00048	0.00229	CcSEcCtD
Prasugrel—Eye disorder—Doxorubicin—uterine cancer	0.000478	0.00228	CcSEcCtD
Prasugrel—Back pain—Epirubicin—uterine cancer	0.000466	0.00222	CcSEcCtD
Prasugrel—Angiopathy—Doxorubicin—uterine cancer	0.000464	0.00221	CcSEcCtD
Prasugrel—Dizziness—Etoposide—uterine cancer	0.000464	0.00221	CcSEcCtD
Prasugrel—Immune system disorder—Doxorubicin—uterine cancer	0.000462	0.0022	CcSEcCtD
Prasugrel—Mediastinal disorder—Doxorubicin—uterine cancer	0.000461	0.0022	CcSEcCtD
Prasugrel—Anaemia—Epirubicin—uterine cancer	0.000445	0.00212	CcSEcCtD
Prasugrel—Rash—Etoposide—uterine cancer	0.000442	0.00211	CcSEcCtD
Prasugrel—Dermatitis—Etoposide—uterine cancer	0.000442	0.00211	CcSEcCtD
Prasugrel—Headache—Etoposide—uterine cancer	0.000439	0.00209	CcSEcCtD
Prasugrel—Leukopenia—Epirubicin—uterine cancer	0.000431	0.00205	CcSEcCtD
Prasugrel—Back pain—Doxorubicin—uterine cancer	0.000431	0.00205	CcSEcCtD
Prasugrel—Cough—Epirubicin—uterine cancer	0.00042	0.002	CcSEcCtD
Prasugrel—Nausea—Etoposide—uterine cancer	0.000417	0.00199	CcSEcCtD
Prasugrel—Hypertension—Epirubicin—uterine cancer	0.000416	0.00198	CcSEcCtD
Prasugrel—Anaemia—Doxorubicin—uterine cancer	0.000412	0.00196	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000407	0.00194	CcSEcCtD
Prasugrel—Leukopenia—Doxorubicin—uterine cancer	0.000399	0.0019	CcSEcCtD
Prasugrel—Anaphylactic shock—Epirubicin—uterine cancer	0.000393	0.00187	CcSEcCtD
Prasugrel—Cough—Doxorubicin—uterine cancer	0.000389	0.00185	CcSEcCtD
Prasugrel—Thrombocytopenia—Epirubicin—uterine cancer	0.000385	0.00183	CcSEcCtD
Prasugrel—Hypertension—Doxorubicin—uterine cancer	0.000385	0.00183	CcSEcCtD
Prasugrel—Skin disorder—Epirubicin—uterine cancer	0.000382	0.00182	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000377	0.0018	CcSEcCtD
Prasugrel—Hypotension—Epirubicin—uterine cancer	0.000367	0.00175	CcSEcCtD
Prasugrel—Anaphylactic shock—Doxorubicin—uterine cancer	0.000364	0.00173	CcSEcCtD
Prasugrel—Thrombocytopenia—Doxorubicin—uterine cancer	0.000356	0.0017	CcSEcCtD
Prasugrel—Skin disorder—Doxorubicin—uterine cancer	0.000353	0.00168	CcSEcCtD
Prasugrel—Dyspnoea—Epirubicin—uterine cancer	0.00035	0.00167	CcSEcCtD
Prasugrel—Hypotension—Doxorubicin—uterine cancer	0.00034	0.00162	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000339	0.00162	CcSEcCtD
Prasugrel—Fatigue—Epirubicin—uterine cancer	0.000339	0.00162	CcSEcCtD
Prasugrel—Dyspnoea—Doxorubicin—uterine cancer	0.000324	0.00155	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000314	0.0015	CcSEcCtD
Prasugrel—Fatigue—Doxorubicin—uterine cancer	0.000314	0.00149	CcSEcCtD
Prasugrel—Body temperature increased—Epirubicin—uterine cancer	0.000311	0.00148	CcSEcCtD
Prasugrel—Hypersensitivity—Epirubicin—uterine cancer	0.00029	0.00138	CcSEcCtD
Prasugrel—Body temperature increased—Doxorubicin—uterine cancer	0.000288	0.00137	CcSEcCtD
Prasugrel—Asthenia—Epirubicin—uterine cancer	0.000282	0.00134	CcSEcCtD
Prasugrel—Diarrhoea—Epirubicin—uterine cancer	0.000269	0.00128	CcSEcCtD
Prasugrel—Hypersensitivity—Doxorubicin—uterine cancer	0.000268	0.00128	CcSEcCtD
Prasugrel—Asthenia—Doxorubicin—uterine cancer	0.000261	0.00124	CcSEcCtD
Prasugrel—Dizziness—Epirubicin—uterine cancer	0.00026	0.00124	CcSEcCtD
Prasugrel—Diarrhoea—Doxorubicin—uterine cancer	0.000249	0.00119	CcSEcCtD
Prasugrel—Rash—Epirubicin—uterine cancer	0.000248	0.00118	CcSEcCtD
Prasugrel—Dermatitis—Epirubicin—uterine cancer	0.000248	0.00118	CcSEcCtD
Prasugrel—Headache—Epirubicin—uterine cancer	0.000246	0.00117	CcSEcCtD
Prasugrel—Dizziness—Doxorubicin—uterine cancer	0.000241	0.00115	CcSEcCtD
Prasugrel—Nausea—Epirubicin—uterine cancer	0.000233	0.00111	CcSEcCtD
Prasugrel—Rash—Doxorubicin—uterine cancer	0.000229	0.00109	CcSEcCtD
Prasugrel—Dermatitis—Doxorubicin—uterine cancer	0.000229	0.00109	CcSEcCtD
Prasugrel—Headache—Doxorubicin—uterine cancer	0.000228	0.00109	CcSEcCtD
Prasugrel—Nausea—Doxorubicin—uterine cancer	0.000216	0.00103	CcSEcCtD
Prasugrel—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000142	0.00789	CbGpPWpGaD
Prasugrel—CYP2B6—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.00014	0.00779	CbGpPWpGaD
Prasugrel—CYP2B6—Metapathway biotransformation—AKR1B1—uterine cancer	0.000137	0.00761	CbGpPWpGaD
Prasugrel—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000133	0.00739	CbGpPWpGaD
Prasugrel—CYP2C9—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000131	0.00729	CbGpPWpGaD
Prasugrel—ALB—Selenium Micronutrient Network—GPX3—uterine cancer	0.000128	0.00716	CbGpPWpGaD
Prasugrel—CYP2C19—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000118	0.00657	CbGpPWpGaD
Prasugrel—CYP2B6—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000115	0.0064	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—IRF1—uterine cancer	0.000111	0.00621	CbGpPWpGaD
Prasugrel—CYP2C19—Metapathway biotransformation—AKR1B10—uterine cancer	0.000111	0.00619	CbGpPWpGaD
Prasugrel—CYP2C9—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000108	0.00599	CbGpPWpGaD
Prasugrel—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000107	0.00596	CbGpPWpGaD
Prasugrel—CYP2C19—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000106	0.00589	CbGpPWpGaD
Prasugrel—CYP2C19—Metapathway biotransformation—AKR1B1—uterine cancer	0.000103	0.00575	CbGpPWpGaD
Prasugrel—ALB—Vitamin B12 Metabolism—MTHFR—uterine cancer	0.000102	0.00569	CbGpPWpGaD
Prasugrel—CYP2C9—Metapathway biotransformation—AKR1B10—uterine cancer	0.000101	0.00564	CbGpPWpGaD
Prasugrel—CYP2B6—Metapathway biotransformation—AKR1C1—uterine cancer	0.0001	0.00559	CbGpPWpGaD
Prasugrel—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	9.76e-05	0.00544	CbGpPWpGaD
Prasugrel—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	9.63e-05	0.00537	CbGpPWpGaD
Prasugrel—CYP2C9—Metapathway biotransformation—AKR1B1—uterine cancer	9.42e-05	0.00525	CbGpPWpGaD
Prasugrel—CYP2B6—Metapathway biotransformation—GPX3—uterine cancer	8.81e-05	0.00491	CbGpPWpGaD
Prasugrel—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	8.75e-05	0.00487	CbGpPWpGaD
Prasugrel—CYP2C19—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	8.68e-05	0.00484	CbGpPWpGaD
Prasugrel—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	8.63e-05	0.00481	CbGpPWpGaD
Prasugrel—ALB—Folate Metabolism—MTHFR—uterine cancer	8.3e-05	0.00463	CbGpPWpGaD
Prasugrel—CYP2B6—Biological oxidations—CYP11A1—uterine cancer	8.29e-05	0.00462	CbGpPWpGaD
Prasugrel—CYP2B6—Metapathway biotransformation—CYP11A1—uterine cancer	8.18e-05	0.00456	CbGpPWpGaD
Prasugrel—ALB—Vitamin B12 Metabolism—CCL2—uterine cancer	7.98e-05	0.00445	CbGpPWpGaD
Prasugrel—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	7.96e-05	0.00444	CbGpPWpGaD
Prasugrel—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	7.91e-05	0.00441	CbGpPWpGaD
Prasugrel—CYP2B6—Metapathway biotransformation—AKR1C3—uterine cancer	7.72e-05	0.0043	CbGpPWpGaD
Prasugrel—CYP2C19—Metapathway biotransformation—AKR1C1—uterine cancer	7.58e-05	0.00422	CbGpPWpGaD
Prasugrel—P2RY12—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	7.53e-05	0.0042	CbGpPWpGaD
Prasugrel—P2RY12—G alpha (i) signalling events—CXCL8—uterine cancer	7.49e-05	0.00417	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—AKR1B10—uterine cancer	7.23e-05	0.00403	CbGpPWpGaD
Prasugrel—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	7.09e-05	0.00395	CbGpPWpGaD
Prasugrel—CYP2C9—Metapathway biotransformation—AKR1C1—uterine cancer	6.91e-05	0.00385	CbGpPWpGaD
Prasugrel—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	6.68e-05	0.00372	CbGpPWpGaD
Prasugrel—CYP2C19—Metapathway biotransformation—GPX3—uterine cancer	6.65e-05	0.00371	CbGpPWpGaD
Prasugrel—ALB—Selenium Micronutrient Network—MTHFR—uterine cancer	6.59e-05	0.00368	CbGpPWpGaD
Prasugrel—ALB—Folate Metabolism—CCL2—uterine cancer	6.5e-05	0.00362	CbGpPWpGaD
Prasugrel—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	6.44e-05	0.00359	CbGpPWpGaD
Prasugrel—P2RY12—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	6.39e-05	0.00356	CbGpPWpGaD
Prasugrel—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	6.35e-05	0.00354	CbGpPWpGaD
Prasugrel—CYP2C19—Biological oxidations—CYP11A1—uterine cancer	6.26e-05	0.00349	CbGpPWpGaD
Prasugrel—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	6.21e-05	0.00346	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	6.19e-05	0.00345	CbGpPWpGaD
Prasugrel—CYP2C19—Metapathway biotransformation—CYP11A1—uterine cancer	6.18e-05	0.00344	CbGpPWpGaD
Prasugrel—CYP2B6—Biological oxidations—CYP19A1—uterine cancer	6.1e-05	0.0034	CbGpPWpGaD
Prasugrel—CYP2C9—Metapathway biotransformation—GPX3—uterine cancer	6.07e-05	0.00338	CbGpPWpGaD
Prasugrel—CYP2B6—Metapathway biotransformation—CYP19A1—uterine cancer	6.02e-05	0.00335	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—RNF43—uterine cancer	5.99e-05	0.00334	CbGpPWpGaD
Prasugrel—P2RY12—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	5.96e-05	0.00332	CbGpPWpGaD
Prasugrel—CYP2C19—Metapathway biotransformation—AKR1C3—uterine cancer	5.83e-05	0.00325	CbGpPWpGaD
Prasugrel—P2RY12—GPCR ligand binding—CCL2—uterine cancer	5.74e-05	0.0032	CbGpPWpGaD
Prasugrel—CYP2C9—Biological oxidations—CYP11A1—uterine cancer	5.71e-05	0.00318	CbGpPWpGaD
Prasugrel—CYP2C9—Metapathway biotransformation—CYP11A1—uterine cancer	5.63e-05	0.00314	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	5.56e-05	0.0031	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—INHBA—uterine cancer	5.48e-05	0.00305	CbGpPWpGaD
Prasugrel—CYP2C9—Metapathway biotransformation—AKR1C3—uterine cancer	5.32e-05	0.00296	CbGpPWpGaD
Prasugrel—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	5.22e-05	0.00291	CbGpPWpGaD
Prasugrel—ALB—Selenium Micronutrient Network—CCL2—uterine cancer	5.16e-05	0.00288	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	5.07e-05	0.00283	CbGpPWpGaD
Prasugrel—P2RY12—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	4.99e-05	0.00278	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—AKR1C1—uterine cancer	4.93e-05	0.00275	CbGpPWpGaD
Prasugrel—CYP2C19—Biological oxidations—CYP19A1—uterine cancer	4.61e-05	0.00257	CbGpPWpGaD
Prasugrel—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	4.56e-05	0.00254	CbGpPWpGaD
Prasugrel—CYP2C19—Metapathway biotransformation—CYP19A1—uterine cancer	4.55e-05	0.00253	CbGpPWpGaD
Prasugrel—P2RY12—GPCR ligand binding—CXCL8—uterine cancer	4.54e-05	0.00253	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—STAR—uterine cancer	4.48e-05	0.0025	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	4.48e-05	0.0025	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—ABCC9—uterine cancer	4.26e-05	0.00237	CbGpPWpGaD
Prasugrel—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	4.2e-05	0.00234	CbGpPWpGaD
Prasugrel—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	4.14e-05	0.00231	CbGpPWpGaD
Prasugrel—P2RY12—Platelet activation, signaling and aggregation—AKT1—uterine cancer	4.08e-05	0.00227	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	4.02e-05	0.00224	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—STAR—uterine cancer	4.02e-05	0.00224	CbGpPWpGaD
Prasugrel—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	4e-05	0.00223	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—AKR1C3—uterine cancer	3.8e-05	0.00212	CbGpPWpGaD
Prasugrel—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	3.77e-05	0.0021	CbGpPWpGaD
Prasugrel—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	3.72e-05	0.00207	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—PGR—uterine cancer	3.7e-05	0.00206	CbGpPWpGaD
Prasugrel—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—uterine cancer	3.68e-05	0.00205	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	3.67e-05	0.00204	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	3.67e-05	0.00204	CbGpPWpGaD
Prasugrel—ALB—Platelet degranulation—VEGFA—uterine cancer	3.58e-05	0.00199	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—YWHAE—uterine cancer	3.53e-05	0.00197	CbGpPWpGaD
Prasugrel—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	3.51e-05	0.00196	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—EP300—uterine cancer	3.48e-05	0.00194	CbGpPWpGaD
Prasugrel—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—uterine cancer	3.41e-05	0.0019	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—FBXW7—uterine cancer	3.38e-05	0.00189	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—VEGFA—uterine cancer	3.29e-05	0.00184	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	3.29e-05	0.00183	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—SRD5A2—uterine cancer	3.28e-05	0.00183	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—NDUFB11—uterine cancer	3.28e-05	0.00183	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—NRAS—uterine cancer	3.25e-05	0.00181	CbGpPWpGaD
Prasugrel—ALB—Folate Metabolism—TP53—uterine cancer	3.15e-05	0.00176	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—STK11—uterine cancer	2.96e-05	0.00165	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	2.95e-05	0.00164	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—CCL2—uterine cancer	2.94e-05	0.00164	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—KRAS—uterine cancer	2.8e-05	0.00156	CbGpPWpGaD
Prasugrel—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	2.77e-05	0.00154	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—SOCS3—uterine cancer	2.77e-05	0.00154	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—IRF1—uterine cancer	2.76e-05	0.00154	CbGpPWpGaD
Prasugrel—ALB—Metabolism—SRD5A2—uterine cancer	2.76e-05	0.00154	CbGpPWpGaD
Prasugrel—ALB—Metabolism—NDUFB11—uterine cancer	2.76e-05	0.00154	CbGpPWpGaD
Prasugrel—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	2.73e-05	0.00152	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	2.69e-05	0.0015	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.68e-05	0.00149	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CDKN2B—uterine cancer	2.65e-05	0.00148	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—IGF1R—uterine cancer	2.57e-05	0.00143	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—PIK3CA—uterine cancer	2.57e-05	0.00143	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—CXCL8—uterine cancer	2.56e-05	0.00143	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.53e-05	0.00141	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—TP53—uterine cancer	2.49e-05	0.00139	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—NDUFB11—uterine cancer	2.48e-05	0.00138	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—SRD5A2—uterine cancer	2.48e-05	0.00138	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—SMAD3—uterine cancer	2.42e-05	0.00135	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.41e-05	0.00134	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—HRAS—uterine cancer	2.38e-05	0.00133	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—AKR1B1—uterine cancer	2.37e-05	0.00132	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—STAR—uterine cancer	2.37e-05	0.00132	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—CXCL8—uterine cancer	2.33e-05	0.0013	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—FGFR2—uterine cancer	2.31e-05	0.00129	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.27e-05	0.00127	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—SRD5A2—uterine cancer	2.26e-05	0.00126	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—NDUFB11—uterine cancer	2.26e-05	0.00126	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.19e-05	0.00122	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—AKT1—uterine cancer	2.1e-05	0.00117	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.07e-05	0.00115	CbGpPWpGaD
Prasugrel—ALB—Metabolism—STAR—uterine cancer	1.99e-05	0.00111	CbGpPWpGaD
Prasugrel—ALB—Metabolism—AKR1B1—uterine cancer	1.99e-05	0.00111	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—ESR1—uterine cancer	1.98e-05	0.0011	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.97e-05	0.0011	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—NRAS—uterine cancer	1.87e-05	0.00104	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—POLD1—uterine cancer	1.86e-05	0.00104	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—AKR1B1—uterine cancer	1.79e-05	0.000998	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—STAR—uterine cancer	1.79e-05	0.000998	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.77e-05	0.000986	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CCL2—uterine cancer	1.74e-05	0.000969	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—AKR1C1—uterine cancer	1.74e-05	0.000969	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—AKR1B1—uterine cancer	1.63e-05	0.00091	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—STAR—uterine cancer	1.63e-05	0.00091	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—PIK3CA—uterine cancer	1.63e-05	0.000906	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.61e-05	0.000899	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—KRAS—uterine cancer	1.61e-05	0.000896	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	1.59e-05	0.000884	CbGpPWpGaD
Prasugrel—ALB—Metabolism—POLD1—uterine cancer	1.57e-05	0.000872	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—RRM2—uterine cancer	1.55e-05	0.000864	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—DCN—uterine cancer	1.5e-05	0.000839	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.49e-05	0.00083	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.49e-05	0.00083	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—PIK3CA—uterine cancer	1.48e-05	0.000823	CbGpPWpGaD
Prasugrel—ALB—Metabolism—AKR1C1—uterine cancer	1.46e-05	0.000816	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—ERBB2—uterine cancer	1.45e-05	0.000808	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—CYP11A1—uterine cancer	1.42e-05	0.00079	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—POLD1—uterine cancer	1.4e-05	0.000783	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CXCL8—uterine cancer	1.38e-05	0.000766	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—HRAS—uterine cancer	1.37e-05	0.000761	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CDKN1B—uterine cancer	1.34e-05	0.000748	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—AKR1C3—uterine cancer	1.34e-05	0.000746	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—AKT1—uterine cancer	1.33e-05	0.00074	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—AKR1C1—uterine cancer	1.31e-05	0.000732	CbGpPWpGaD
Prasugrel—ALB—Metabolism—RRM2—uterine cancer	1.3e-05	0.000727	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—POLD1—uterine cancer	1.28e-05	0.000714	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CTNNB1—uterine cancer	1.27e-05	0.000707	CbGpPWpGaD
Prasugrel—ALB—Metabolism—DCN—uterine cancer	1.27e-05	0.000706	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	1.24e-05	0.00069	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—PTEN—uterine cancer	1.24e-05	0.000689	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—AKT1—uterine cancer	1.21e-05	0.000672	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—AKR1C1—uterine cancer	1.2e-05	0.000668	CbGpPWpGaD
Prasugrel—ALB—Metabolism—CYP11A1—uterine cancer	1.19e-05	0.000665	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—EP300—uterine cancer	1.18e-05	0.000657	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—RRM2—uterine cancer	1.17e-05	0.000653	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—DCN—uterine cancer	1.14e-05	0.000634	CbGpPWpGaD
Prasugrel—ALB—Metabolism—AKR1C3—uterine cancer	1.13e-05	0.000628	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—VEGFA—uterine cancer	1.12e-05	0.000622	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—NRAS—uterine cancer	1.1e-05	0.000615	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—STAR—uterine cancer	1.08e-05	0.0006	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—AKR1B1—uterine cancer	1.08e-05	0.0006	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—CYP11A1—uterine cancer	1.07e-05	0.000597	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—RRM2—uterine cancer	1.07e-05	0.000595	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—STK11—uterine cancer	1.04e-05	0.000581	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—CYP19A1—uterine cancer	1.04e-05	0.000581	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—DCN—uterine cancer	1.04e-05	0.000578	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—AKT1—uterine cancer	1.01e-05	0.000564	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—AKR1C3—uterine cancer	1.01e-05	0.000564	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—CYP11A1—uterine cancer	9.77e-06	0.000544	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—KRAS—uterine cancer	9.49e-06	0.000529	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—AKR1C3—uterine cancer	9.22e-06	0.000514	CbGpPWpGaD
Prasugrel—ALB—Metabolism—CYP19A1—uterine cancer	8.78e-06	0.000489	CbGpPWpGaD
Prasugrel—ALB—Metabolism—STK11—uterine cancer	8.78e-06	0.000489	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—PIK3CA—uterine cancer	8.72e-06	0.000486	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—EP300—uterine cancer	8.63e-06	0.000481	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—POLD1—uterine cancer	8.45e-06	0.000471	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—TP53—uterine cancer	8.44e-06	0.00047	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	8.24e-06	0.000459	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—VEGFA—uterine cancer	8.18e-06	0.000456	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—NRAS—uterine cancer	8.08e-06	0.00045	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—HRAS—uterine cancer	8.07e-06	0.00045	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—AKR1C1—uterine cancer	7.9e-06	0.00044	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—STK11—uterine cancer	7.88e-06	0.000439	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—CYP19A1—uterine cancer	7.88e-06	0.000439	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.86e-06	0.000438	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—MTHFR—uterine cancer	7.84e-06	0.000437	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.4e-06	0.000412	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—STK11—uterine cancer	7.19e-06	0.0004	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—CYP19A1—uterine cancer	7.19e-06	0.0004	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—AKT1—uterine cancer	7.13e-06	0.000397	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.06e-06	0.000393	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—RRM2—uterine cancer	7.04e-06	0.000393	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—KRAS—uterine cancer	6.95e-06	0.000387	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—DCN—uterine cancer	6.84e-06	0.000381	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.75e-06	0.000376	CbGpPWpGaD
Prasugrel—ALB—Metabolism—MTHFR—uterine cancer	6.6e-06	0.000368	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—CYP11A1—uterine cancer	6.44e-06	0.000359	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.43e-06	0.000359	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—PIK3CA—uterine cancer	6.39e-06	0.000356	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—TP53—uterine cancer	6.18e-06	0.000344	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—AKR1C3—uterine cancer	6.08e-06	0.000339	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—MTHFR—uterine cancer	5.92e-06	0.00033	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—HRAS—uterine cancer	5.91e-06	0.000329	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.81e-06	0.000324	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—MTHFR—uterine cancer	5.4e-06	0.000301	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.22e-06	0.000291	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—AKT1—uterine cancer	5.22e-06	0.000291	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.76e-06	0.000265	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—CYP19A1—uterine cancer	4.74e-06	0.000264	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—STK11—uterine cancer	4.74e-06	0.000264	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PTEN—uterine cancer	4.36e-06	0.000243	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—EP300—uterine cancer	4.16e-06	0.000232	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PTEN—uterine cancer	3.67e-06	0.000205	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—MTHFR—uterine cancer	3.56e-06	0.000198	CbGpPWpGaD
Prasugrel—ALB—Metabolism—EP300—uterine cancer	3.5e-06	0.000195	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PTEN—uterine cancer	3.29e-06	0.000184	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—EP300—uterine cancer	3.14e-06	0.000175	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PIK3CA—uterine cancer	3.08e-06	0.000171	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PTEN—uterine cancer	3e-06	0.000167	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—EP300—uterine cancer	2.87e-06	0.00016	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PIK3CA—uterine cancer	2.59e-06	0.000144	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—AKT1—uterine cancer	2.51e-06	0.00014	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PIK3CA—uterine cancer	2.32e-06	0.00013	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PIK3CA—uterine cancer	2.12e-06	0.000118	CbGpPWpGaD
Prasugrel—ALB—Metabolism—AKT1—uterine cancer	2.12e-06	0.000118	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PTEN—uterine cancer	1.98e-06	0.00011	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—AKT1—uterine cancer	1.9e-06	0.000106	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—EP300—uterine cancer	1.89e-06	0.000105	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—AKT1—uterine cancer	1.73e-06	9.65e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.4e-06	7.79e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—AKT1—uterine cancer	1.14e-06	6.36e-05	CbGpPWpGaD
